Murat Sayan 47 32. Niesters HG, Pas S, de Man RA. Detection of hepatitis B virus genotypes and mutants: current status. J Clin Virol. 2005;34 Suppl 1:S4-8. 33. Lok AS, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol. 2002;40(10):3729-34. 34. Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007;20(3):426-39, table of contents. 35. Karatayli E, Karayalcin S, Karaaslan H, et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther. 2007;12(5):761-8. 36. Tran N, Berne R, Chann R, et al. European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. J Clin Microbiol. 2006;44(8):2792-800. 37. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44(6):1656-65. 38. Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 2007;46(3):531-8. 39. Bidgoli AS, Daryani NE, Motamedi M, Miri A, Poorsamimi P. Evaluation of possible risk factors of lamivudine resistance in chronic hepatitis b patients: a retrospective study in Iran. Hepat Mon. 2009;9(3):171-9. 40. Sablon E, Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci. 2005;2(1):8-16. Hepatitis Monthly, Winter 2010; 10(1): 42-47